I agree that this site is using cookies. You can find further informations here.
X
Ferrannini, G
188  results:
Search for persons X
?
1

High mannose correlates with surrogate indexes of insulin r..:

Fortin, E ; Campi, B ; Ferrannini, E...
European Heart Journal.  44 (2023)  Supplement_2 - p. , 2023
Link: https://doi.org/10.1093/..
 
?
2

The management of patients with heart failure in Sweden: a ..:

Ferrannini, G ; Biber, M E ; Abdi, S...
European Heart Journal.  44 (2023)  Supplement_2 - p. , 2023
Link: https://doi.org/10.1093/..
 
?
3

Association between body mass index and outcomes in heart f..:

Ferrannini, G ; Rodolico, D ; Amario, D D...
European Heart Journal.  44 (2023)  Supplement_2 - p. , 2023
Link: https://doi.org/10.1093/..
 
?
4

Measures of insulin resistance as a screening tool for dysg..:

Ferrannini, G ; De Bacquer, D ; Erlund, I...
European Heart Journal.  43 (2022)  Supplement_2 - p. , 2022
Link: https://doi.org/10.1093/..
 
?
5

Does dulaglutide impact a composite outcome reflecting athe..:

Ferrannini, G ; Mellbin, L ; Kirabo, F...
European Heart Journal.  43 (2022)  Supplement_2 - p. , 2022
Link: https://doi.org/10.1093/..
 
?
6

Periodontitis and cardiovascular outcome – a prospective fo..:

Ferrannini, G ; Norhammar, A ; Almosawi, M...
European Heart Journal.  42 (2021)  Supplement_1 - p. , 2021
Link: https://doi.org/10.1093/..
 
?
7

Long term outcome after a first myocardial infarction:

Almosawi, M ; Ferrannini, G ; Buhlin, K...
European Heart Journal.  42 (2021)  Supplement_1 - p. , 2021
Link: https://doi.org/10.1093/..
 
?
8

Dulaglutide is cardioprotective with or without background ..:

Ferrannini, G ; Gerstein, H.C ; Colhoun, H.M...
European Heart Journal.  41 (2020)  Supplement_2 - p. , 2020
Link: https://doi.org/10.1093/..
 
?
9

Association between use of novel glucose-lowering drugs and..:

Ferrannini, G ; Lund, LH ; Benson, L...
https://openaccess.sgul.ac.uk/id/eprint/114747/6/pvac044.pdf.  , 2023
Link: https://openaccess.sgul...
 
?
10

Differential Proteomics of Cardiovascular Risk and Coronary..:

Ferrannini E ; Manca M. L ; Ferrannini G...
info:eu-repo/semantics/altIdentifier/pmid/35187107.  , 2022
Link: https://hdl.handle.net/2..
 
?
11

Use of sodium-glucose co-transporter 2 inhibitors in patien..:

Becher, PM ; Schrage, B ; Ferrannini, G...
https://openaccess.sgul.ac.uk/id/eprint/113286/1/ejhf.2131.pdf.  , 2021
Link: https://openaccess.sgul...
 
?
12

Use of sodium–glucose co-transporter 2 inhibitors in patien..:

Becher P. M ; Schrage B ; Ferrannini G...
info:eu-repo/semantics/altIdentifier/pmid/33599357.  , 2021
Link: http://hdl.handle.net/11..
 
?
13

Effects of treatment for acromegaly on Bone Mineral Density..:

BRIGANTE, Giulia ; SANTI, Daniele ; DIAZZI, Chiara...
ispartofbook:Abstracts of The 95th Annual Meeting of the Endocrine Society ENDO2013.  , 2013
Link: http://hdl.handle.net/11..
 
?
14

Glucagon-like peptide-1 receptor agonists use and associati..:

Wallner, Markus ; Biber, Mattia Emanuele ; Stolfo, Davide...
European Heart Journal - Cardiovascular Pharmacotherapy.  10 (2024)  4 - p. 296-306 , 2024
Link: https://doi.org/10.1093/..
 
?
15

Eligibility for vericiguat in a real‐world heart failure po..:

Nguyen, Ngoc V. ; Lindberg, Felix ; Benson, Lina...
European Journal of Heart Failure.  25 (2023)  8 - p. 1418-1428 , 2023
Link: https://doi.org/10.1002/..
 
1-15